Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 11-17

  Franks, Zechariah G ^a   Campbell, Robert A ^a   Weyrich, Andrew S ^a   Rondina, Matthew T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet agents; Leukocytes; Platelets; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; CD40 LIGAND; CLOPIDOGREL; DIPYRIDAMOLE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PLACEBO; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTITHROMBOCYTIC AGENT;

BLEEDING; BRAIN ISCHEMIA; CELL INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOEMBOLISM; ANIMAL; BLOOD; PHYSIOLOGY; RISK FACTOR;

ANIMALS; BLOOD PLATELETS; BRAIN ISCHEMIA; HUMANS; INFLAMMATION; LEUKOCYTES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 78149276162     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05733.x     Document Type: Review

References (55)

1. Lloyd-Jones, D. et al. 2010. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e46-e215.
2. Born, G. & C. Patrono. 2006. Antiplatelet drugs. Br. J. Pharmacol. 147(Suppl 1): S241-S251.
3. Mateen, F.J. & A. Shuaib. 2007. Progress in clinical neurosciences: the 'antiplatelet' agents and the role of the endothelium. Can. J. Neurol. Sci. 34: 270-279.
4. Badimon, L., G. Vilahur & T. Padro. 2009. Lipoproteins, platelets and atherothrombosis. Rev. Esp. Cardiol. 62: 1161-1178.
5. Lowenberg, E.C., J.C. Meijers & M. Levi. 2010. Platelet-vessel wall interaction in health and disease.Neth. J. Med. 68: 242-251.
6. Bergmeier, W. & D.D. Wagner. 2007. Inflammation. In Platelets, 2nd ed. A.D. Michelson, Ed.: 719-726. Elsevier. San Diego.
7. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
8. Glass, C.K. & J.L. Witztum. 2001. Atherosclerosis: the road ahead. Cell 104: 503-516.
9. Weber, C., A. Zernecke & P. Libby. 2008. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol. 8: 802-815.
10. Huo, Y. & L. Xia. 2009. P-selectin glycoprotein ligand-1 plays a crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial wall. Trends Cardiovasc.Med. 19: 140-145.
11. Koyama, H. et al. 2003. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 108: 524-529.
12. Shoji, T. et al. 2006. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 188: 190-195.
13. Davi, G. et al. 1998. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 97: 953-957.
14. Htun, P. et al. 2006.Course of platelet activation and plateletleukocyte interaction in cerebrovascular ischemia. Stroke 37: 2283-2287.
15. Burger, P.C. & D.D. Wagner. 2003. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101: 2661-2666.
16. Dong, Z.M., A.A. Brown & D.D. Wagner. 2000. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 101: 2290-2295.
17. Dong, Z. M. et al. 1998. The combined role of P- and Eselectins in atherosclerosis. J. Clin. Invest. 102: 145-152.
18. Manka, D. et al. 2001. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 103: 1000-1005.
19. Henn, V. et al. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.Nature 391: 591-594.
20. Antoniades, C. et al. 2009. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J. Am. Coll. Cardiol. 54: 669-677.
21. von Hundelshausen, P. et al. 2001. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777.
22. Weyrich, A.S. et al. 1996. Activated platelets signal chemokine synthesis by human monocytes. J. Clin. Invest. 97: 1525-1534.
23. Weyrich, A.S. & G.A. Zimmerman. 2004. Platelets: signaling cells in the immune continuum. Trends Immunol. 25: 489-495.
24. Lindemann, S. et al. 2001. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J. Cell Biol. 154: 485-490.
25. McIntyre, T.M. et al. 2003. Cell-cell interactions: leukocyteendothelial interactions. Curr. Opin. Hematol. 10: 150-158.
26. Weyrich, A.S. et al. 1995. Monocyte tethering by P-selectin regulatesmonocyte chemotactic protein-1 and tumornecrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J. Clin. Invest. 95: 2297-2303.
27. Dixon, D. A. et al. 2006. Expression of COX-2 in plateletmonocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J. Clin. Invest. 116: 2727-2738.
28. FitzGerald, G.A. 2003. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2: 879-890.
29. Schmidt, R. et al. 2008. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaBdependent inflammation in monocytes. Circ. Res. 102: 302-309.
30. Schuett, H. et al. 2009. Howmuch is toomuch? Interleukin-6 and its signalling in atherosclerosis. Thromb.Haemost. 102: 215-222.
31. Galt, S.W. et al. 2001. Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ. Res. 89: 509-516.
32. Schonbeck, U. & P. Libby. 2001. CD40 signaling and plaque instability. Circ. Res. 89: 1092-1103.
33. Kostulas, N. et al. 1998. Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke 29: 462-466.
34. Kostulas, N. et al. 1999. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 30: 2174-2179.
35. Welsh, P. et al. 2008. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 39: 2226-2230.
36. Campbell, D.J. et al. 2006. Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch. Neurol. 63: 60-65.
37. Worthmann, H. et al. 2010. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc. Dis. 30: 85-92.
38. van Kooten, F. et al. 1997. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 28: 1557-1563.
39. van Kooten, F. et al. 1999. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 30: 546-549.
40. Baigent, C., R. Collins & R. Peto. 2002. Articlemakes simple errors and could cause unnecessary deaths. BMJ 324: 167.
41. Sacco, R.L. et al. 2006. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113: e409-e449.
42. Albers, G.W. et al. 2008. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 630S-669S.
43. Diener, H.C. et al. 1996. European Stroke Prevention Study. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143: 1-13.
44. Johnson, E.S. et al. 1999. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch. Intern. Med. 159: 1248-1253.
45. Adams, R.J. et al. 2008.Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39: 1647-1652.
46. Halkes, P.H. et al. 2006. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665-1673.
47. Verro, P., P.B. Gorelick & D. Nguyen. 2008. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 39: 1358-1363.
48. Simmons, B.B., A. Yeo & K. Fung. 2010. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. Postgrad. Med. 122: 49-53.
49. CAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339.
50. Sacco, R.L. et al. 2008. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359: 1238-1251.
51. Diener, H.C., R. Sacco & S. Yusuf. 2007. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc. Dis. 23: 368-380.
52. Shin, W.S., A. Szuba & S.G. Rockson. 2002. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160: 91-102.
53. Weyrich, A.S. et al. 2005. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 111: 633-642.
54. Klinkhardt, U. et al. 2003. Clopidogrel but not aspirin reduces P-selectin expression and formation of plateletleukocyte aggregates in patientswith atherosclerotic vascular disease. Clin. Pharmacol. Ther. 73: 232-241.
55. Storey, R.F. et al. 2002. Inhibition of ADP-induced Pselectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist ARC69931MX but not aspirin. Thromb. Haemost. 88: 488-494.